Status:
COMPLETED
Clinical Outcome of Liver Transplant Patients With Tacrolimus-based Immunosuppression
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Liver Transplantation
Eligibility:
All Genders
20-65 years
Brief Summary
Genetic polymorphism and numerous clinical factors could influence tacrolimus pharmacokinetics, which led to large inter-and intra-individual variability.Since its narrow therapeutic range,predicting ...
Detailed Description
A great number of studies had found significant correlation between tacrolimus pharmacokinetics and gene polymorphism. However, previous studies on the correlation between genetic factors and clinical...
Eligibility Criteria
Inclusion
- Eligible patients were those who had signed informed consent for genetic study in our previous research projects.
- Inclusion Criteria of the Previous Study:
- patients who underwent living-donor liver transplantation during January 2008 to December 2017
- at the age of 20-65
- with tacrolimus-based immunosuppression after liver transplant for at least 6 months.
- Exclusion Criteria of the Previous Study :
- retransplantation
- multi-organ transplantation
- human immunodeficiency virus (HIV) positive.
Exclusion
Key Trial Info
Start Date :
June 6 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2020
Estimated Enrollment :
113 Patients enrolled
Trial Details
Trial ID
NCT03800576
Start Date
June 6 2019
End Date
September 22 2020
Last Update
March 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan